254 related articles for article (PubMed ID: 8402636)
1. Caffeine prevents apoptosis and cell cycle effects induced by camptothecin or topotecan in HL-60 cells.
Traganos F; Kapuscinski J; Gong J; Ardelt B; Darzynkiewicz RJ; Darzynkiewicz Z
Cancer Res; 1993 Oct; 53(19):4613-8. PubMed ID: 8402636
[TBL] [Abstract][Full Text] [Related]
2. Different patterns of apoptosis of HL-60 cells induced by cycloheximide and camptothecin.
Gong J; Li X; Darzynkiewicz Z
J Cell Physiol; 1993 Nov; 157(2):263-70. PubMed ID: 8227159
[TBL] [Abstract][Full Text] [Related]
3. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue.
Hendricks CB; Rowinsky EK; Grochow LB; Donehower RC; Kaufmann SH
Cancer Res; 1992 Apr; 52(8):2268-78. PubMed ID: 1348448
[TBL] [Abstract][Full Text] [Related]
4. The modulation of the DNA-damaging effect of polycyclic aromatic agents by xanthines. Part I. Reduction of cytostatic effects of quinacrine mustard by caffeine.
Kapuscinski J; Ardelt B; Piosik J; Zdunek M; Darzynkiewicz Z
Biochem Pharmacol; 2002 Feb; 63(4):625-34. PubMed ID: 11992630
[TBL] [Abstract][Full Text] [Related]
5. The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents.
Gorczyca W; Gong J; Ardelt B; Traganos F; Darzynkiewicz Z
Cancer Res; 1993 Jul; 53(13):3186-92. PubMed ID: 8319228
[TBL] [Abstract][Full Text] [Related]
6. Subcellular redistribution of DNA topoisomerase I in anaplastic astrocytoma cells treated with topotecan.
Danks MK; Garrett KE; Marion RC; Whipple DO
Cancer Res; 1996 Apr; 56(7):1664-73. PubMed ID: 8603418
[TBL] [Abstract][Full Text] [Related]
7. Caffeine modulates the effects of DNA-intercalating drugs in vitro: a flow cytometric and spectrophotometric analysis of caffeine interaction with novantrone, doxorubicin, ellipticine, and the doxorubicin analogue AD198.
Traganos F; Kapuscinski J; Darzynkiewicz Z
Cancer Res; 1991 Jul; 51(14):3682-9. PubMed ID: 2065324
[TBL] [Abstract][Full Text] [Related]
8. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864).
Mattern MR; Hofmann GA; McCabe FL; Johnson RK
Cancer Res; 1991 Nov; 51(21):5813-6. PubMed ID: 1657371
[TBL] [Abstract][Full Text] [Related]
9. Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH.
Gabr A; Kuin A; Aalders M; El-Gawly H; Smets LA
Cancer Res; 1997 Nov; 57(21):4811-6. PubMed ID: 9354443
[TBL] [Abstract][Full Text] [Related]
10. In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues.
Emerson DL; Besterman JM; Brown HR; Evans MG; Leitner PP; Luzzio MJ; Shaffer JE; Sternbach DD; Uehling D; Vuong A
Cancer Res; 1995 Feb; 55(3):603-9. PubMed ID: 7834631
[TBL] [Abstract][Full Text] [Related]
11. Camptothecin, teniposide, or 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induces degradation of nuclear DNA in the S phase of HL-60 cells.
Del Bino G; Darzynkiewicz Z
Cancer Res; 1991 Feb; 51(4):1165-9. PubMed ID: 1997159
[TBL] [Abstract][Full Text] [Related]
12. Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan.
Subramanian D; Muller MT
Oncol Res; 1995; 7(9):461-9. PubMed ID: 8835290
[TBL] [Abstract][Full Text] [Related]
13. Diverse effects of camptothecin, an inhibitor of topoisomerase I, on the cell cycle of lymphocytic (L1210, MOLT-4) and myelogenous (HL-60, KG1) leukemic cells.
Del Bino G; Skierski JS; Darzynkiewicz Z
Cancer Res; 1990 Sep; 50(18):5746-50. PubMed ID: 2168279
[TBL] [Abstract][Full Text] [Related]
14. Intermittent exposure of medulloblastoma cells to topotecan produces growth inhibition equivalent to continuous exposure.
Danks MK; Pawlik CA; Whipple DO; Wolverton JS
Clin Cancer Res; 1997 Oct; 3(10):1731-8. PubMed ID: 9815557
[TBL] [Abstract][Full Text] [Related]
15. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors.
Dubrez L; Goldwasser F; Genne P; Pommier Y; Solary E
Leukemia; 1995 Jun; 9(6):1013-24. PubMed ID: 7596166
[TBL] [Abstract][Full Text] [Related]
16. Cytostatic and cytotoxic effects of fostriecin on human promyelocytic HL-60 and lymphocytic MOLT-4 leukemic cells.
Hotz MA; Del Bino G; Lassota P; Traganos F; Darzynkiewicz Z
Cancer Res; 1992 Mar; 52(6):1530-5. PubMed ID: 1540962
[TBL] [Abstract][Full Text] [Related]
17. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note.
Kaufmann SH
Cancer Res; 1989 Nov; 49(21):5870-8. PubMed ID: 2790800
[TBL] [Abstract][Full Text] [Related]
18. Altered susceptibility of differentiating HL-60 cells to apoptosis induced by antitumor drugs.
Del Bino G; Li X; Traganos F; Darzynkiewicz Z
Leukemia; 1994 Feb; 8(2):281-8. PubMed ID: 7508535
[TBL] [Abstract][Full Text] [Related]
19. The expression of Bcl-XL, Bcl-XS and p27Kip1 in topotecan-induced apoptosis in hepatoblastoma HepG2 cell line.
Zhang J; Cheng C; He CL; Zhou YJ; Cao Y
Cancer Invest; 2008 Jun; 26(5):456-63. PubMed ID: 18568767
[TBL] [Abstract][Full Text] [Related]
20. Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens.
Cheng MF; Chatterjee S; Berger NA
Oncol Res; 1994; 6(6):269-79. PubMed ID: 7865902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]